Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medical supply

- PMLiVE

Novartis files CAR-T therapy CTL109 in Europe

Analysts predict Kymriah could become a $1bn-plus product in Europe

EU flag

EU’s 10-year paediatric meds report – not bad, but can do better

Paper highlights the lack of ‘major therapeutic advances’ in children’s medicine

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

- PMLiVE

Freedom of movement ‘unlocks’ scientific success

Nature study finds mobility gave researchers higher citation rates than those who remained in their homeland

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

- PMLiVE

AAA’s orphan drug Lutathera wins EU green light

The first-in-class drug treats adults with GEP-NET

- PMLiVE

Hard Brexit could cost UK healthcare sector £2bn per year

Pharma and medical supply firms may face 10% revenue drop

Brexit implications for UK pharma legislation

What are the potential options and outcomes of the negotiations?

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

Macron, Merkel and May: implications of the 2017 elections for the life science industry

Political instability and policy continuity in Europe’s biggest economies mean a worsening commercial environment stacked with uncertainty

- PMLiVE

NICE: We’re the institute of ‘yes’

But Meindert Boysen says affordability conversations with pharma need to happen earlier

- PMLiVE

UK life sciences sector sets out its post-Brexit growth proposals

Review helmed by Sir John Bell outlines a wide-ranging strategy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links